Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions
Name
s42003-020-01470-7.pdf
Description
Published version
Size
1.7 MB
Format
Adobe PDF
Checksum (MD5)
af4a02d1485ae2beebeaa767b1f9faf1
Author(s)
Chatterjee, Pranam
Ponnapati, Manvitha
Kramme, Christian
Plesa, Alexandru M.
Church, George M.
Jacobson, Joseph
Date Issued
November 2020
Journal
Communications Biology
Publisher
Springer Science and Business Media LLC
Citation
Chattergee, Pranam et al. "Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions." Communications Biology 3, 1 (November 2020): 715 © 2020 The Author(s)
Version
Final published version
Abstract
The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has elicited a global health crisis of catastrophic proportions. With only a few vaccines approved for early or limited use, there is a critical need for effective antiviral strategies. In this study, we report a unique antiviral platform, through computational design of ACE2-derived peptides which both target the viral spike protein receptor binding domain (RBD) and recruit E3 ubiquitin ligases for subsequent intracellular degradation of SARS-CoV-2 in the proteasome. Our engineered peptide fusions demonstrate robust RBD degradation capabilities in human cells and are capable of inhibiting infection-competent viral production, thus prompting their further experimental characterization and therapeutic development.
MIT Department
Massachusetts Institute of Technology. Center for Bits and Atoms
Massachusetts Institute of Technology. Media Laboratory
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/s42003-020-01470-7
